A self-expanding percutaneous valve for patients with pulmonary regurgitation and an enlarged native right ventricular outflow tract: one-year results

Zhou, Daxin; Pan, Wenzhi; Jilaihawi, Hasan; Zhang, Gejun; Feng, Yuan; Pan, Xin; Liu, Jinfen; Yu, Shi-Qiang; Cao, Qi‐Ling; Ge, Junbo

doi:10.4244/eij-d-18-00715

Cited by 28 publications

(37 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The differences between the RVOT dimensions on CMR and balloon interrogation made the latter a mandatory step. [ 11 12 13 14 15 16 17 ] After placing a stiff Lunderquist guidewire (Cook medical, Bloomington, IN) to straighten the outflow tract, marker pigtail angiograms were performed in orthogonal projections to measure the RVOT dimensions. Once the hemodynamics was recorded, a long compliant AGA sizing balloon (Abbott, Plymouth, MN) was inflated across the outflow until a right ventriculogram confirmed complete occlusion.…”

Section: Methodsmentioning

confidence: 99%

“…In the third design, this thin pericardial lining was removed from the six open cells in the distal flare. [ 11 12 13 14 ] The fourth design since 2018 had five open cells in distal flare that connected all the sharp edges to the outer wire frame [ Figure 1 ]. The valve was rinsed to remove the glutaraldehyde preservative and crimped in ice-cold saline to reduce the nitinol memory, using a proprietary compression device and loaded on the delivery system.…”

Section: Methodsmentioning

confidence: 99%

“…[ 11 12 13 ] The initial experience has been encouraging for both designs. [ 10 11 12 13 14 15 16 17 ] Reports from China, South America, Thailand, and Europe describe patients implanted with Venus P-valve. [ 10 11 12 13 14 15 16 17 ] The device still awaits approval for clinical use from the regulatory bodies.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Outcomes of Venus P-valve for dysfunctional right ventricular outflow tracts from Indian Venus P-valve database

et al. 2021

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Outcomes of Venus P-valve for dysfunctional right ventricular outflow tracts from Indian Venus P-valve database

et al. 2021

View full text Add to dashboard Cite

“…Table 3 summarizes clinical studies of the commercially approved valves and the new self-expanding valves reported in the literature. Early experience with these valves, although limited, has been encouraging, suggesting that self-expandable pulmonary valves can be implanted safely in patients with native RVOTs, with good short-and mid-term results [55][56][57][58][59][60][61][62].…”

Section: Future Perspectivesmentioning

confidence: 99%

The Future of Paediatric Heart Interventions: Where Will We Be in 2030?

Kogure

Qureshi

2020

Curr Cardiol Rep

View full text Add to dashboard Cite

Purpose of Review Cardiac catheterization therapies to treat or palliate infants, children and adults with congenital heart disease have developed rapidly worldwide in both technical innovation and device development in the previous three decades. By reviewing of current status of novel or development of devices and techniques, we will discuss what is likely to happen in paediatric heart intervention in the next decade. Recent Findings Recently, biodegradable stents and devices, transcatheter pulmonary valve implantation for the native right ventricle outflow tract and MRI-guided interventions have been progressing rapidly with good immediate to early results. These are expected to be introduced and spread in the next decade although there are still challenges to overcome. Summary The future of paediatric heart intervention is very promising with rapid development of technological progress.

show abstract

“…Although the implant numbers are very small, we have not seen endocarditis on this valve yet. This holds true for the multiple published cohorts of the flared Venus P-valve™ with one exception from a multi-center Chinese experience 32. In this cohort (n = 55) studied by Zhou et al one patient died of endocarditis within 1 year of implantation of a flared Venus P-valve™.5 | LIMITATIONSThis study suffers from the usual disadvantages of a multicentre, retrospective cohort.…”

mentioning

confidence: 93%

Early clinical experience with the straight design of Venus P‐valve™ in dysfunctional right ventricular outflow tracts

Morgan

Sivakumar

Promphan

et al. 2020

Cathet Cardio Intervent

View full text Add to dashboard Cite

Objectives: To assess the initial procedural and short to medium-term experience with the straight design of the Venus P-valve™ (Venus MedTech, Hangzhou, China) in dysfunctional right ventricular outflow tracts (RVOT). Background: The Melody™ valve (Medtronic, Minneapolis, Minnesota) has been the only percutaneous valve option for smaller RVOT conduits. The straight Venus P-valve™ may provide an alternative to the Melody™ valve. Methods: Retrospective data collection of patient characteristics, procedural data, clinical and imaging follow-up of the straight Venus P-valve™. Results: Nine patients (four female) with a mean age of 23.1 ± 7.5 years and a mean weight of 72.7 ± 29.4 kg underwent straight Venus P-valve™ implantation between 03/2014 and 06/2016. All patients had right ventricle-to-pulmonary artery conduits which were pre-stented before the valve implantation. All valves were deployed successfully without any significant procedural complications. During the mean followup of 24 ± 9.1 months, there were no valve related re-interventions or deterioration in valve performance. There was one case of insignificant, single wire frame fracture and no cases of endocarditis. The cohort demonstrated a reduction in pulmonary regurgitation and tricuspid regurgitation, which was sustained throughout the followup. Similarly the gradient across the RVOT tract did not significantly increase. Conclusions: Implantation of the straight Venus P-valve™ has provided satisfactory short to mid-term results with high success rates and no complications and may be considered as an alternative option in patients with RVOT dysfunction. K E Y W O R D S congenital heart disease, percutaneous intervention, transcatheter pulmonary valve 1 | INTRODUCTION Developments in percutaneous pulmonary valve technology have expanded rapidly in the last 10 years. 1-8 The most recent focus has been on the major area of unmet need, the large regurgitant "native" outflow tract. 9-16 This expansion has combined the development of innovative techniques to apply currently available

show abstract

A self-expanding percutaneous valve for patients with pulmonary regurgitation and an enlarged native right ventricular outflow tract: one-year results

Cited by 28 publications

References 17 publications

Outcomes of Venus P-valve for dysfunctional right ventricular outflow tracts from Indian Venus P-valve database

Outcomes of Venus P-valve for dysfunctional right ventricular outflow tracts from Indian Venus P-valve database

The Future of Paediatric Heart Interventions: Where Will We Be in 2030?

Early clinical experience with the straight design of Venus P‐valve™ in dysfunctional right ventricular outflow tracts

Contact Info

Product

Resources

About